Menkes Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Menkes disease (also known as Menkes kinky hair syndrome or copper transport disease) is a rare, X-linked recessive neurodegenerative disorder caused by mutations in the ATP7A gene, which encodes a copper-transporting P-type ATPase 1(https://www.ncbi.nlm.nih.gov/books/NBK1413/). The disease results in systemic copper deficiency due to impaired intestinal copper absorption and defective intracellular copper trafficking, leading to severe progressive neurodegeneration and multisystem dysfunction 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/).
Menkes disease affects approximately 1 in 100,000 to 250,000 live births worldwide, with higher prevalence reported in some populations such as Australia (1 in 50,000–100,000) 3(https://www.nature.com/articles/ejhg2009187). As an X-linked disorder, it predominantly affects males, while female carriers are usually asymptomatic. The disease was first described by John Hans Menkes and colleagues in 1962, who reported five male infants in a single family with severe neurological deterioration, peculiar hair, and failure to thrive 4(https://rarediseases.org/rare-diseases/menkes-disease/).
Menkes disease is classified within the spectrum of ATP7A-related copper transport disorders, which ranges from classic Menkes disease (most severe) through mild Menkes disease to occipital horn syndrome (OHS, the mildest form) 1(https://www.ncbi.nlm.nih.gov/books/NBK1413/). The clinical severity correlates with the degree of residual ATP7A function.
The ATP7A gene is located on chromosome Xq21.1 and spans approximately 140 kb of genomic DNA, containing 23 exons 1(https://www.ncbi.nlm.nih.gov/books/NBK1413/). It encodes a 1,500-amino-acid copper-transporting P-type ATPase (also called Menkes protein or MNK) that plays a critical role in cellular copper homeostasis. Over 350 different pathogenic variants have been identified, including deletions, insertions, missense, nonsense, and splice-site mutations 5(https://www.nature.com/articles/nrneurol.2010.180).
The ATP7A protein performs two essential functions in copper metabolism 5(https://www.nature.com/articles/nrneurol.2010.180):
In intestinal enterocytes, ATP7A is essential for transporting absorbed dietary copper from the intestinal epithelium into the portal circulation. In the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--, ATP7A facilitates copper transport into the central nervous system 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/).
The deficiency of copper delivery to cuproenzymes underlies the diverse clinical manifestations of Menkes disease 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/):
| Enzyme | Function | Clinical Consequence of Deficiency |
|---|---|---|
| Cytochrome c oxidase | Mitochondrial electron transport | Hypothermia, muscle weakness |
| Dopamine beta-hydroxylase | Converts [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- to [norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine--TEMP--/entities)--FIX-- | Temperature instability, hypotension |
| Lysyl oxidase | Collagen and elastin crosslinking | Connective tissue laxity, vascular tortuosity |
| Tyrosinase | Melanin synthesis | Hypopigmentation |
| Superoxide dismutase | [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- defense | Neuronal vulnerability to oxidative damage |
| Peptidylglycine alpha-amidating monooxygenase | Neuropeptide processing | Neuroendocrine dysfunction |
The neurodegeneration in Menkes disease results from a combination of copper-dependent enzyme deficiencies and direct neurotoxic effects of copper maldistribution 5(https://www.nature.com/articles/nrneurol.2010.180):
Lysyl oxidase deficiency leads to defective crosslinking of collagen and elastin in blood vessel walls, resulting in tortuous and fragile cerebral arteries 3(https://www.nature.com/articles/ejhg2009187). Brain MR angiography characteristically reveals a "corkscrew" appearance of cerebral vessels, and subdural hemorrhages or hematomas may occur.
Impaired lysyl oxidase function also affects bone, skin, and joints, producing osteoporosis, cutis laxa, bladder diverticula, and joint hypermobility 4(https://rarediseases.org/rare-diseases/menkes-disease/).
Classic Menkes disease typically presents in a biphasic pattern 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/):
Neonatal period (birth to 2–3 months):
Infantile period (2–3 months onward):
Some ATP7A mutations that permit partial residual function produce a milder phenotype with later onset, slower progression, and longer survival 1(https://www.ncbi.nlm.nih.gov/books/NBK1413/). The G727R mutation is an example of a copper-responsive variant associated with improved outcomes when treated early with copper supplementation 7(https://pmc.ncbi.nlm.nih.gov/articles/PMC2654537/).
Occipital horn syndrome (OHS), the mildest ATP7A-related phenotype, is characterized by 8(https://omim.org/entry/309400):
Menkes disease should be suspected in any male infant presenting with seizures, developmental regression, hypotonia, and characteristic hair abnormalities after an initially normal neonatal period 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/).
Brain MRI reveals 3(https://www.nature.com/articles/ejhg2009187):
Identification of a hemizygous pathogenic variant in ATP7A by molecular genetic testing confirms the diagnosis 1(https://www.ncbi.nlm.nih.gov/books/NBK1413/). Carrier testing and prenatal diagnosis are available for families with a known mutation.
Microscopic examination of hair shafts reveals pili torti (twisted hair), monilethrix (beaded hair), and trichorrhexis nodosa 4(https://rarediseases.org/rare-diseases/menkes-disease/).
In 2023, copper histidinate injection (ZYCUBO) became the first and only FDA-approved treatment for Menkes disease 9(https://sentynl.com/news/zycubo-fda-approval/). Key aspects of this therapy:
[Gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX-- represents the most promising approach for Menkes disease, particularly for patients with severe loss-of-function mutations where copper replacement alone is inadequate 11(https://www.science.org/doi/10.1126/sciadv.adw5612):
The brain shows diffuse atrophy of the cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--, with ventriculomegaly and reduced white matter volume 2(https://www.ncbi.nlm.nih.gov/books/NBK560917/).
Menkes disease shares pathogenic mechanisms and clinical features with several other neurodegenerative conditions:
The study of Menkes Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.